Impaired Myostatin Function Alters Body Composition Without Detectable Attenuation of Imiquimod-Induced Psoriasiform Dermatitis.
5 affiliations
- 1Department of Dermatology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.
- 2Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki 701-0192, Japan.
- 3Laboratory of Immunology, Faculty of Veterinary Medicine, Okayama University of Science, Imabari 794-8555, Japan.
- 4Department of Natural Sciences, Kawasaki Medical School, Kurashiki 701-0192, Japan.
- 5Department of Neurology, Kawasaki Medical School, Kurashiki 701-0192, Japan.
Abstract
Psoriasis is a chronic inflammatory skin disease closely associated with obesity and metabolic dysfunction. While excess adiposity is considered a key risk factor, the independent contribution of body composition to psoriatic inflammation remains unclear. Myostatin negatively regulates skeletal muscle growth, and its inhibition leads to muscle hypertrophy and reduced adiposity. In this study, we investigated whether altered body composition due to impaired myostatin function affects imiquimod (IMQ)-induced psoriasiform dermatitis. Wild-type (WT) and dominant-negative myostatin transgenic mice were fed either a normal diet or a high-fat diet (HFD) for 10 weeks, followed by topical IMQ treatment to induce dermatitis. Mutant mice exhibited increased skeletal muscle mass and reduced visceral fat compared with WT controls, indicating marked changes in body composition. In WT mice, HFD feeding increased fat mass and tended to aggravate IMQ-induced ear swelling. In contrast, no significant effect of impaired myostatin function on ear thickness, epidermal hyperplasia, or the expression of psoriasis-associated genes was detected, despite reduced visceral fat. Under the present experimental conditions, these changes in body composition were not associated with a detectable attenuation of psoriasiform skin inflammation. Our results suggest that obesity-related psoriasis is influenced by metabolic and immunological factors beyond body composition.
Related
- A novel MSMO1 variant presenting with severe psoriasiform dermatitis: A case from Saudi Arabia
- Combination of Clinical Frailty Score and Myostatin Concentrations as Mortality Predictor in Hemodialysis Patients
- Galectin-1 deficiency attenuates imiquimod-induced psoriasiform skin inflammation and is associated with reduced macrophage recruitment
- Prophylactic Soraphen A Treatment Attenuates Western Diet‐Exacerbated IMQ‐Induced Psoriasiform Inflammation
- Case Report: Dupilumab-associated psoriasiform eruption followed by depigmentation in a patient with prurigo nodularis and Vogt-Koyanagi-Harada disease
BibTeX
@article{matsuda2026impaired,
title = {{Impaired Myostatin Function Alters Body Composition Without Detectable Attenuation of Imiquimod-Induced Psoriasiform Dermatitis.}},
author = {Yoshihiro Matsuda and Shin Morizane and Yuma Sakamoto and Nobuyasu Baba and Masanori Iseki and Daiki Takezaki and Yoshio Kawakami and Shin-Ichiro Nishimatsu and Yutaka Ohsawa and Yoshihide Sunada and Tomoyuki Mukai},
journal = {International journal of molecular sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198518},
url = {https://europepmc.org/article/MED/42883765},
note = {CC BY},
}
RIS
TY - JOUR
TI - Impaired Myostatin Function Alters Body Composition Without Detectable Attenuation of Imiquimod-Induced Psoriasiform Dermatitis.
AU - Yoshihiro Matsuda
AU - Shin Morizane
AU - Yuma Sakamoto
AU - Nobuyasu Baba
AU - Masanori Iseki
AU - Daiki Takezaki
AU - Yoshio Kawakami
AU - Shin-Ichiro Nishimatsu
AU - Yutaka Ohsawa
AU - Yoshihide Sunada
AU - Tomoyuki Mukai
PY - 2026
DA - 2026/09/24
JO - International journal of molecular sciences
DO - 10.3390/ijms27198518
UR - https://europepmc.org/article/MED/42883765
AB - Psoriasis is a chronic inflammatory skin disease closely associated with obesity and metabolic dysfunction. While excess adiposity is considered a key risk factor, the independent contribution of body composition to psoriatic inflammation remains unclear. Myostatin negatively regulates skeletal muscle growth, and its inhibition leads to muscle hypertrophy and reduced adiposity. In this study, we investigated whether altered body composition due to impaired myostatin function affects imiquimod (IMQ)-induced psoriasiform dermatitis. Wild-type (WT) and dominant-negative myostatin transgenic mice were fed either a normal diet or a high-fat diet (HFD) for 10 weeks, followed by topical IMQ treatment to induce dermatitis. Mutant mice exhibited increased skeletal muscle mass and reduced visceral fat compared with WT controls, indicating marked changes in body composition. In WT mice, HFD feeding increased fat mass and tended to aggravate IMQ-induced ear swelling. In contrast, no significant effect of impaired myostatin function on ear thickness, epidermal hyperplasia, or the expression of psoriasis-associated genes was detected, despite reduced visceral fat. Under the present experimental conditions, these changes in body composition were not associated with a detectable attenuation of psoriasiform skin inflammation. Our results suggest that obesity-related psoriasis is influenced by metabolic and immunological factors beyond body composition.
SN - 1422-0067
ER -